About Libo Pharma
Founded in 2017, Libo Pharma Corp. is dedicated to developing innovative therapies that address significant unmet medical needs. Our lead asset, NM-IL-12, is a first-in-class cytokine-based immunomodulator with multiple mechanisms of action, including immune regulation, hematopoiesis enhancement, radiation damage mitigation, and anti-tumor activity.
Our Lead Product: NM-IL-12
NM-IL-12 has received orphan drug designation from both the U.S. FDA and European Medicines Agency (EMA) for the treatment of cutaneous T-cell lymphoma (CTCL) and is advancing into a Phase 3 clinical trial, with strong potential for regulatory approval and commercialization.
The product has also completed Phase 2 clinical trials for Hematopoietic Syndrome of Acute Radiation Syndrome(HSARS) and open wound healing, and is currently expanded into new indications including diffuse large B-cell lymphoma (DLBCL) and other solid tumors—highlighting a robust and diversified pipeline.
Innovation & Capabilities
Libo Pharma maintains a globally competitive intellectual property portfolio, covering key markets such as the United States, Europe, and Japan. We retain full control over the manufacturing processes and biological materials related to NM-IL-12, ensuring a high level of autonomy across product development and production.
Backed by a highly experienced scientific and regulatory team, we are well-positioned to drive forward our development programs from clinical validation to commercial launch.
Clinical Experience
To date, NM-IL-12 has been administered in over 200 human subjects, consistently demonstrating a favorable safety and efficacy profile. Its ability to be used in combination with standard therapies including chemotherapy, radiotherapy, and immune checkpoint inhibitors offers promising opportunities to enhance treatment outcomes across multiple cancer types.
Company Details
- Employees
- 9
- Founded
- -
- Address
- No. 36, Nanjing W. Rd., Datong Dist., 9f-1,taiwan, Province Of China
- Industry
- Biotechnology
- Website
- http://www.libopharma.com
- Keywords
- Show more similar pages.
- HQ
- Taipei City, Taiwan
Libo Pharma Corp. Questions
Libo Pharma Corp.'s website is http://www.libopharma.com
Libo Pharma Corp.'s LinkedIn profile is https://tw.linkedin.com/company/libo-pharma-corp
Libo Pharma Corp. has
9 employees.
View email and phone details for 9
employees at Libo Pharma Corp..
Libo Pharma Corp.'s industry is
Biotechnology
Libo Pharma Corp.'s top competitors are
Always Champion Enterprise Co., Ltd.,
Ahead Medicine,
Emerald Clinical,
Fundacja Eb Polska,
Boehringer Ingelheim,
Novotech,
Stemcyte Inc.,
Creatively.io,
Bora Pharmaceuticals,
Eirgenix, Inc..
Libo Pharma Corp.'s categories are Biotechnology
Libo Pharma Corp.'s founding year is 2017
